| Budget Amount *help |
¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
Fiscal Year 2011: ¥7,410,000 (Direct Cost: ¥5,700,000、Indirect Cost: ¥1,710,000)
Fiscal Year 2010: ¥13,910,000 (Direct Cost: ¥10,700,000、Indirect Cost: ¥3,210,000)
|
|---|
| Research Abstract |
We found that transient type I IFN signaling induced HSC activation and chronic type I IFN signaling further reduced the number of quiescent HSCs. Based on our findings, we established type I IFN-based preconditioning regimen without irradiation for HSC transplantation, which is applicable to the treatment of a congenital metabolic disorder, mucopolysaccharidosis type VII. In addition, the treatment of chronic myeroid leukemia(CML) with imatinib and poly(I : C), a type I IFN inducer, significantly reduced the recurrence rate of the disease.
|
